A New Milestone (002219): Acquisitions continue to be implemented, and the pace of high-quality asset injection accelerates
A New Milestone (002219): “Yinfa Economy's First Stock” Endogenous Management Steadily Enhances Epitaxial Asset Injection and Sails Off
New Mileage (002219): Acquisition of the assets of Chongqing Xinmileage's controlling shareholder launched the “first shot” *Ma Shuai and He Xin
New Milestones (002219): High-quality hospitals take the opportunity to inject and gradually reap the benefits of the company's continued expansion of operations
New Mileage (002219): Main business is stable, focusing on fixed growth
New Mileage (002219): “Medical+Pharmaceutical” two-wheel drive high-quality asset injection is worth looking forward to
New Milestone (002219): Comprehensive Healthcare Group Leader's Asset Injection Rhythm Is Clear
New Mileage (002219) Company Dynamics Research Report: Effective Corporate Governance, Steady Progress in Three-Year High-Quality Development Strategy
A new milestone (002219): Performance is in line with expectations, and the profitability of the medical service business continues to improve
New Milestone (002219): Performance meets expectations and accelerates construction of new hospitals
SDIC Securities released a research report on April 18 stating that the target price for the new mileage (002219.SZ) purchase rating will be 3.24 yuan. The main reasons for the rating include: 1) performance is in line with expectations, excluding the inf
New Mileage (002219): Healthcare Service Industry Leader 1+N Model Continues to Expand
A New Milestone (002219): Continued Improvement of Business Quality and Steady Growth in Medical Service Business
A New Milestone (002219): Steady Growth in Performance, Continued Implementation of Hospital Expansion Projects
New Milestone (002219): The “first stock” of a general hospital with gradual increase in profitability and promising epitaxial development
New Milestones (002219): Asset Reorganization Completed, Comprehensive Healthcare Group Leader Sails Sailing
Research Report: Nuggets 丨 Pacific Securities: HKUST iFLYTEK Spark Releases, Domestic AI Leader Maintains “Buy” Rating at New Mileage
Hengkang Medical (002219) interim report review: Steady growth in medical business, Chinese medicine tablets benefit from good maintainability of its hospital channel business
Hengkang Healthcare (002219): Delisting risk alert cancels full normalization of company operations and hospital mergers and acquisitions
Hengkang Medical (002219) Review: The adverse factors affecting the development of listed companies affected by the completion of the audit case were completely eliminated